Retevmo (Selpercatinib) for Lung Cancer | MyLungCancerTeam

Connect with others who understand.

sign up Log in
About MyLungCancerTeam
Powered By

Retevmo is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic, rearranged-during-transfection (RET) fusion-positive, non-small cell lung cancer. Retevmo is also referred to by its drug name, selpercatinib.

Retevmo is a member of a class of drugs called tyrosine kinase inhibitors. Retevmo is believed to work by inhibiting RET, a kinase involved in tumor invasion, migration, and proliferation (increase), thereby slowing the growth and spread of tumors.

How do I take it?
Prescribing information states that Retevmo is taken orally as a capsule twice daily.

Retevmo should be taken exactly as prescribed by a physician.

Side effects
The FDA-approved label for Retevmo lists common side effects including high blood sugar levels, low white blood cell counts, compromised liver function, dry mouth, diarrhea, high blood pressure, fatigue, edema (swelling), and constipation.

Rare but serious side effects listed for Retevmo include liver damage, abnormal heart rhythms, hemorrhage, severe allergic reactions, impaired wound healing, and fetal harm.

For more details about this treatment, visit:

Retevmo — Eli Lilly

Selpercatinib (Oral Route) — Mayo Clinic

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in